top of page
This site was designed with the
.com
website builder. Create your website today.Start Now

Wearable Technologies Help Reduce The Clinical Trial Time


Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson’s disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%. For instance, in 2016, Michael J. Fox Foundation for Parkinson’s Research collaborated with specialty drugmaker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson’s disease. Biogen, a leading CNS drugmaker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer’s disease research.

CENTRAL NERVOUS SYSTEM DRUGS MARKET TO GROW TO $83 BILLION BY 2020 ACCORDING TO THE BUSINESS RESEARCH COMPANY

The Business Research Company expects the global central nervous system drugs market to grow from $68 billion in 2016 to $83 billion in 2020 at a compound annual growth rate (CAGR) of 5.0%. North America was the largest region in the central nervous system drugs market in 2016, accounting for $25 billion or 38.0% market share. This can be attributed to high per capita spending on drugs to treat central nervous system disorders, the aging population and the insurance system which supports high healthcare costs in the USA.

The chart below shows the year-on-year growth of the global central nervous system drugs market during 2016-2020

According to The Business Research Company’s Healthcare and Biotechnology Consultant, Ravikiran drug manufacturers are increasingly using biomarkers to improve CNS drug development process. A biomarker is a biological variable which has a statistically significant relationship with parameters of disease states or drug candidates. It can be used to diagnose or predict disease, monitor disease progression and predict treatment response. Examples of biomarkers include protein levels, axonal damage, pulse, blood pressure and complex laboratory tests of blood and other tissues. Biomarkers can increase the statistical power of clinical trials and predict drug accuracy better than conventional clinical endpoints. This enhances product development and results in more effective treatments. The global CNS biomarker market is expected to grow at a CAGR of 20.7% through 2017, thus indicating a significant potential for biomarkers in this industry. Major drugmakers such as Pfizer, Biogen, Amgen, Novartis AG, Merck, Eli Lilly and Sanofi are involved in CNS biomarker drug development.

Biogen Idec was the largest company in the central nervous system drugs market in 2016 with revenues of $8.3 billion for the financial year 2016 from divisions involved in central nervous system drugs manufacturing. Biogen Idec’s growth strategy is to develop and expanding its neurology portfolio. In this regard, the company acquired UK-based clinical-stage biopharmaceutical company Convergence Pharmaceuticals, in January 2015. Convergence Pharmaceuticals offers ion channel-modulating products that can be used to treat neuropathic pain. In addition, with sales of its drugs growing in the US, Biogen Idec is expanding its manufacturing capacity in the country. In February 2015, the company added 100 more employees to its plant in Research Triangle Park, North Carolina.

The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities. Top selling neurological drugs in 2016 include Copaxone, Lyrica, and Tecfidera.

The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

The central nervous system drugs market can be classified as follows –

  • Analgesics

  • Anti-Parkinson Drugs

  • Anesthetics

  • Anti-Epileptics Drugs (AED)

  • Antiemetics

  • Muscle Relaxants

  • Sedatives

Central Nervous System Drugs is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office the price is $6000 and $8000 if you wish to use across a multinational company.

About The Business Research Company

Visit TheBusinessResearchCompany.com, mail info@tbrc.info or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.

The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.

It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.

The Business Research Company's management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations.


bottom of page